HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NUTX
Nutex Health, Inc.
NUTX's fundamentals are mixed: it turned 31% of its revenue into free cash flow, but revenue fell 19%. At 7.2x earnings, it's trading below its usual 8.7x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NUTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
NUTX's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NUTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $171 | — |
| Current | 7.2x | $171 | — |
| Cheap | 7.3x | $174 | +1.7% |
| Fair | 8.7x | $208 | +21% |
| Expensive | 11x | $255 | +49% |
Historical ranges are pointers, not guarantees.
NUTX's PE is in its cheap range at 7.2x. If earnings grow as analysts expect, today's price would be 6.4x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NUTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NUTX's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NUTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.68 | +11% |
| Q3 2026 | $23.95 | +24% |
| Q2 2026 | $26.00 | +166% |
| Q1 2026 | $13.67 | +8% |
| Q4 2025 | $10.48 | +14% |
| Q3 2025 | $19.26 | +$28.65 |
| Q2 2025 | $9.78 | +$18.95 |
| Q1 2025 | $12.66 | +$23.26 |
| Q4 2024 | $9.23 | +$21.23 |
NUTX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NUTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $217.6M | -19% |
| Q2 2026 | $210.8M | -14% |
| Q1 2026 | $216.5M | +2.2% |
| Q4 2025 | $151.7M | -41% |
| Q3 2025 | $267.8M | +240% |
| Q2 2025 | $244M | +221% |
| Q1 2025 | $211.8M | +214% |
| Q4 2024 | $257.6M | +270% |
NUTX's revenue has slid since its 2025 peak: $218M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -13 points |
| Q2 2026 | 58% | +44 points |
| Q1 2026 | 38% | -0.6 points |
| Q4 2025 | 20% | -24 points |
| Q3 2025 | 49% | +36 points |
| Q2 2025 | 14% | +6.8 points |
| Q1 2025 | 38% | +36 points |
| Q4 2024 | 44% | +82 points |
NUTX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
NUTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.1M | -26% |
| Q2 2026 | $31.7M | +19% |
| Q1 2026 | $74.3M | +46% |
| Q4 2025 | $69M | +$69.3M |
| Q3 2025 | $99.2M | +1507% |
| Q2 2025 | $26.5M | +109% |
| Q1 2025 | $50.9M | +2096% |
| Q4 2024 | -$341.8K | +$608.8K |
NUTX generated $248M in free cash flow over the past year, up 41% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NUTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NUTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +20.7K shares |
| 1 year | -1.9% | -136K shares |
| 3 years | +59% | +2.6M shares |
NUTX has 7M diluted shares, down 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $19M |
| Q1 2026 | $31.7M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NUTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.0x | Net Cash |
NUTX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NUTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.9 | Neutral |
NUTX's weekly RSI is 48 (neutral) and its Stochastic is 43 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NUTX PE vs Healthcare Sector
| Metric | NUTX | Sector median | Relative |
|---|---|---|---|
| PE | 7.2x | 26x | 72% below |
| PE % | 13 | 29 | 16 pts below |
NUTX is trading at 7.2x earnings, a 72% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NUTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $198.8 | 14% below |
| 20 week MA | $187.7 | 8.7% below |
| 50 week MA | $153.5 | 12% above |
| 100 week MA | $123.4 | 39% above |
| 200 week MA | $86.9 | 97% above |
NUTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NUTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $301.5 | $157.5 | -48% |
| 2021 | $157.5 | $619.5 | +293% |
| 2022 | $619.5 | $312.0 | -50% |
| 2023 | $312.0 | $27.0 | -91% |
| 2024 | $27.0 | $31.9 | +18% |
| 2025 | $31.9 | $176.7 | +455% |
| 2026 YTD | $176.7 | $171.4 | -3% |
NUTX has the edge over HIMS on returns for 2026, with the stronger performance.